Replicate Bioscience unveils promising clinical progress on self-amplifying RNA at ASGCT annual meeting

SOPHIA ANTIPOLIS, France – May 13, 2024 │ KnowMade actively follows therapeutic mRNA news for its Therapeutic mRNA patent monitor service! What’s new today?

REPLICATE BIOSCIENCE develops novel self-amplifying RNA (or self-replicating or srRNA) technology for use across a range of application (i.e., infectious disease, oncology, or autoimmune disease). This clinical-stage company was already identified as important players for self-amplifying mRNA development in KNOWMADE’s Q2 2023 analysis and in the 2023’s IP activity summary. The advantage of SA mRNA therapy compared to the conventional mRNA technique, is in terms of its lower dosage requirements, relatively fewer side effects, and possessing long-lasting effects.

Last week, REPLICATE BIOSCIENCE presented new preclinical data and shared interim clinical trial results from an ongoing Phase 1 study at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7–11, in Baltimore, Maryland. According to REPLICATE’s press release, results highlight the strong immunogenicity and favorable safety profile of RBI-4000, a prophylactic rabies vaccine, in the Phase 1 trial, which is the first clinical validation of REPLICATE’s next-generation SA mRNA technology. Selected additional takeaways are as follows:

  • Self-Replicating mRNA allows lower dose than conventional mRNA vaccine
  • A complete protection was achieved after a two-doses regimen
  • RBI-4000 was well tolerated with no severe adverse events across all cohorts; reactogenicity was transient and self-limiting
  • No dose limiting toxicity (DLT) was observed; maximum tolerated dose (MTD) has not been reached, enabling further dose escalation

For an overview of KNOWMADE’s activities dedicated to mRNA therapeutics see the dedicated webpage. If you require additional information, please reach us at or with our contact form.

Press contact
Le Drakkar, 2405 route des Dolines, 06560 Valbonne Sophia Antipolis, France

About the author
Elodie Bovier, PhD., works at KnowMade as a Patent Analyst in the field of Biotechnology and Life Sciences. She holds a PhD in genetic and molecular biology from the Paris Sud University. She also holds the Industrial Property International Studies Diploma (in Patent and Trademark & Design Law) from the CEIPI (Strasbourg, France).

About KnowMade
KnowMade is a technology intelligence and IP strategy consulting company specialized in analyzing patents and scientific publications. The company helps innovative companies, investors, and R&D organizations to understand competitive landscape, follow technological evolutions, reduce uncertainties, and identify opportunities and risks in terms of technology and intellectual property.
KnowMade’s analysts combine their strong technology expertise and in-depth knowledge of patents with powerful analytics tools and methodologies to turn patent information and scientific literature into actionable insights, providing high added value reports for decision makers working in R&D, innovation strategy, intellectual property, and marketing. Our experts provide prior art search, patent landscape analysis, freedom-to-operate analysis, IP due diligence, and monitoring services.
KnowMade has a solid expertise in Compound Semiconductors, Power Electronics, Batteries, RF Technologies & Wireless Communications, Solid-State Lighting & Display, Photonics, Memories, MEMS & Sensors, Semiconductor Packaging, Medical Devices, Medical Imaging, Microfluidics, Biotechnology, Pharmaceutics, and Agri-Food.